Skip to main content

E4orf1 Suppresses E1B-Deleted Adenovirus Vaccine-Induced Immune Responses

Publication ,  Journal Article
Sangare, K; Hait, SH; Moore, M; Hogge, C; Hoang, T; Rahman, MA; Venzon, DJ; Labranche, C; Montefiori, D; Robert-Guroff, M; Thomas, MA
Published in: Vaccines
February 1, 2022

As demonstrated by the recent COVID pandemic, vaccines can reduce the burden arising from infectious agents. Adenoviruses (Ads) with deletion of the early region 1B55K (ΔE1B Ad) are currently being explored for use in vaccine delivery. ΔE1B Ads are different from Ads with deletions in early region 1 and early region 3 (ΔE1/E3) used in most Ad vaccine vectors in that they contain the Ad early region 1A (E1A), and therefore the ability to replicate. Common to almost all Ads that are being explored for clinical use is the Ad early region 4 (E4). Among the E4 genes is open reading frame 1 (E4orf1), which mediates signals through the PI3-kinase/Akt pathway that is known to modulate immune responses. This suggests that E4orf1 might also modulate immune responses, although it has remained unexplored in ΔE1B Ad. Here, we show that cells infected with an E1B55K and E4orf1-deleted (ΔE41) Ad exhibited reduced levels of phosphorylated Akt (Ser473 and Thr308)) and expressed different intrinsic innate immune cytokines from those induced in cells infected with an E4orf1-containing, ΔE1B parental Ad that exhibited elevated levels of phosphorylated Akt. Rhesus macaques immunized with a ΔE41 Ad that expressed rhFLSC (HIV-1BaL gp120 linked to rhesus CD4 D1 and D2), exhibited higher levels of rhFLSC-specific interferon γ-producing memory T-cells, higher titers of rhFLSC-specific IgG1 binding antibody in serum, and antibodies able to mediate antibody-dependent cellular cytotoxicity (ADCC) with greater killing capacity than the ΔE1B Ad. Therefore, E4orf1, perhaps by acting through the PI3-kinase/Akt pathway, limits intrinsic innate and system-wide adaptive immune responses that are important for improved ΔE1B Adbased vaccines.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Vaccines

DOI

EISSN

2076-393X

Publication Date

February 1, 2022

Volume

10

Issue

2

Related Subject Headings

  • 3207 Medical microbiology
  • 3204 Immunology
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Sangare, K., Hait, S. H., Moore, M., Hogge, C., Hoang, T., Rahman, M. A., … Thomas, M. A. (2022). E4orf1 Suppresses E1B-Deleted Adenovirus Vaccine-Induced Immune Responses. Vaccines, 10(2). https://doi.org/10.3390/vaccines10020295
Sangare, K., S. H. Hait, M. Moore, C. Hogge, T. Hoang, M. A. Rahman, D. J. Venzon, et al. “E4orf1 Suppresses E1B-Deleted Adenovirus Vaccine-Induced Immune Responses.” Vaccines 10, no. 2 (February 1, 2022). https://doi.org/10.3390/vaccines10020295.
Sangare K, Hait SH, Moore M, Hogge C, Hoang T, Rahman MA, et al. E4orf1 Suppresses E1B-Deleted Adenovirus Vaccine-Induced Immune Responses. Vaccines. 2022 Feb 1;10(2).
Sangare, K., et al. “E4orf1 Suppresses E1B-Deleted Adenovirus Vaccine-Induced Immune Responses.” Vaccines, vol. 10, no. 2, Feb. 2022. Scopus, doi:10.3390/vaccines10020295.
Sangare K, Hait SH, Moore M, Hogge C, Hoang T, Rahman MA, Venzon DJ, Labranche C, Montefiori D, Robert-Guroff M, Thomas MA. E4orf1 Suppresses E1B-Deleted Adenovirus Vaccine-Induced Immune Responses. Vaccines. 2022 Feb 1;10(2).

Published In

Vaccines

DOI

EISSN

2076-393X

Publication Date

February 1, 2022

Volume

10

Issue

2

Related Subject Headings

  • 3207 Medical microbiology
  • 3204 Immunology
  • 3202 Clinical sciences